|drug1559||Hydroxycloroquine and Azythromycine Wiki||1.00|
|drug2215||No intervention Wiki||0.20|
|D016638||Critical Illness NIH||0.13|
|D011024||Pneumonia, Viral NIH||0.11|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non inferiority test aimed to compare the efficacy and safety in add on to Azithromycin, an antimalarial drug, a treatment combination of the antimalrial drug with an antiviral phytomedicine versus Hydroxychloroquine in COVID-19 patients without complications. During the treatment, viral clearance, adverse effects related to treatment, and symptoms progression will be assessed on days 3, 6 and 14. Clinical, paraclinical and laboratory tests will be performed throughout the 3-month trial. Ethical and deontological considerations will be applied.
Description: Virological clearance from admission to discharge at days 3, 6 and 14Measure: Virological clearance of throat swabs or lower respiratory tract secretions Time: day 3 to day 14
Description: number of patients who developed treatment-related adverse effectsMeasure: Adverse effects Time: day 1 to day 14
Description: number of patients whose conditions worsenedMeasure: Worsened conditions Time: day 1 to day 14
Description: number of patients whose fever, cough and any other clinical sign observed on introduction have resolvedMeasure: COVID-19 symptoms Time: day 1 to day 14
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports